Domperidone vs. Metoclopramide for Gastroparesis: A Patient's Comparison Guide

Prokinetic medications — drugs that accelerate gastric emptying — are the cornerstone of pharmacological treatment for gastroparesis. The two most commonly prescribed prokinetics are metoclopramide (Reglan) and domperidone. Both work by blocking dopamine receptors in the gut, which increases the strength and coordination of gastric contractions. But they differ significantly in their side effect profiles, their central nervous system effects, and their availability — differences that matter enormously for patients who need long-term treatment.

This guide compares domperidone and metoclopramide in depth, covering their mechanisms, efficacy, side effects, and the practical question of how to access domperidone in the United States, where it is not FDA-approved.

How Both Medications Work

Both metoclopramide and domperidone are dopamine D2 receptor antagonists. Dopamine normally inhibits gastric motility — it slows gastric emptying and reduces the strength of antral contractions. By blocking dopamine D2 receptors in the stomach and small intestine, both medications remove this inhibitory signal, allowing the stomach to contract more forcefully and empty more quickly.

Both medications also block dopamine receptors in the chemoreceptor trigger zone (CTZ) — the area of the brain that triggers nausea and vomiting — which is why both have antiemetic (anti-nausea) effects in addition to their prokinetic effects.

The critical difference between the two medications is their ability to cross the blood-brain barrier.

The Blood-Brain Barrier: The Key Difference

Metoclopramide crosses the blood-brain barrier freely. This means it blocks dopamine receptors not just in the gut and CTZ, but throughout the central nervous system. Dopamine is a critical neurotransmitter in the brain — it is essential for movement control (in the basal ganglia), mood regulation (in the limbic system), and prolactin secretion (in the pituitary). When metoclopramide blocks dopamine receptors throughout the brain, it produces a range of central nervous system side effects that can be severe and, in some cases, irreversible.

Domperidone does not cross the blood-brain barrier (or crosses it only minimally). It blocks dopamine receptors in the gut and CTZ — which are outside the blood-brain barrier — but has minimal effects on dopamine receptors in the brain itself. This means domperidone produces the same prokinetic and antiemetic effects as metoclopramide without the central nervous system side effects.

Side Effect Comparison

Tardive dyskinesia is the most serious risk of metoclopramide. This is a potentially irreversible movement disorder characterized by repetitive, involuntary movements — typically of the face, tongue, and lips (lip smacking, tongue protrusion, grimacing) but also of the limbs. The risk increases with duration of use and cumulative dose. The FDA mandates a black box warning on metoclopramide stating that use beyond 12 weeks is associated with tardive dyskinesia. Despite this warning, many patients with gastroparesis require long-term treatment — creating a significant clinical problem.

QT prolongation is the primary concern with domperidone. Domperidone blocks hERG potassium channels in the heart, which can prolong the QT interval on ECG. Prolonged QT increases the risk of a potentially fatal arrhythmia called torsades de pointes. This risk is highest in patients who are already at risk for QT prolongation (those with cardiac disease, electrolyte abnormalities, or taking other QT-prolonging medications). Regular ECG monitoring is required for patients on domperidone.

Efficacy Comparison

Both medications are effective prokinetics for gastroparesis. Head-to-head comparison studies are limited, but the available evidence suggests:

• Both medications produce similar improvements in gastric emptying time
• Both medications produce similar improvements in nausea and vomiting
• Domperidone may be better tolerated long-term due to its superior central nervous system safety profile
• Some patients who do not respond to one medication respond to the other

The choice between the two is therefore primarily driven by the side effect profile and the patient's individual risk factors, rather than by differences in efficacy.

Accessing Domperidone in the United States

Domperidone is not FDA-approved in the United States. The FDA withdrew its approval in 1986 due to concerns about cardiac arrhythmias when given intravenously (a formulation no longer used). Oral domperidone has a much better cardiac safety profile than IV domperidone, and it remains approved and widely used in Canada, the UK, Europe, Australia, and most of the world.

Despite not being FDA-approved, domperidone can be legally accessed in the United States through several pathways:

FDA Expanded Access (Compassionate Use) Program. The FDA has a formal program allowing physicians to prescribe domperidone for individual patients with serious conditions (including gastroparesis) when standard treatments have failed. The physician submits an Investigational New Drug (IND) application to the FDA. This process takes 1–4 weeks and is approved in the vast majority of cases. The medication is then obtained through a compounding pharmacy.

Compounding pharmacies. Once a physician has FDA approval through the expanded access program, a compounding pharmacy prepares the domperidone. The cost is typically $50–$150 per month, depending on the dose and pharmacy.

International pharmacies. Some patients obtain domperidone from Canadian or European pharmacies with a prescription from their US physician. This is technically a gray area legally, but personal importation of small quantities for personal use is generally tolerated by US customs.

Steps to access domperidone through expanded access:

1. Ask your gastroenterologist or motility specialist about domperidone
2. The physician submits an IND application to the FDA (Form FDA 3926)
3. FDA approval is typically granted within 1–4 weeks
4. The physician writes a prescription for a compounding pharmacy
5. The compounding pharmacy prepares the domperidone (typically 10–20 mg tablets or suspension)

ECG requirements. Before starting domperidone, a baseline ECG should be obtained to assess the QT interval. A QTc > 450 ms (women) or > 440 ms (men) is a relative contraindication. Repeat ECG should be performed 1–2 weeks after starting domperidone and periodically thereafter.

Which Medication Is Right for You?

Consider metoclopramide if:

• You need short-term treatment (< 3 months) and the tardive dyskinesia risk is acceptable
• You have significant QT prolongation or cardiac risk factors that make domperidone more dangerous
• Cost is a significant concern (metoclopramide is inexpensive and widely available)
• You are taking other medications that prolong the QT interval

Consider domperidone if:

• You need long-term treatment (> 3 months)
• You have had side effects from metoclopramide (sedation, depression, movement symptoms)
• You are young (tardive dyskinesia risk from metoclopramide is higher in younger patients)
• You have a history of depression or anxiety (metoclopramide can worsen both)
• You have a normal baseline QTc and no significant cardiac risk factors

For patients with POTS and gastroparesis: Metoclopramide can worsen orthostatic symptoms in some POTS patients, possibly because it affects central dopamine signaling. Domperidone is generally better tolerated in POTS patients and is the preferred prokinetic in the POTS-gastroparesis population.